SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is facing intense community debate as investors weigh concerns over potential dilution and future stock splits against optimism surrounding the commercial traction and insurance coverage expansion of their lead product, Tonmya. While some shareholders are selling amid downward price pressure and a history of capital raises, others are aggressively buying the dip, citing strong long-term pipeline fundamentals and recent insider share purchases as evidence of an impending turnaround.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors digest long-term Week 40 Phase 3 data, which demonstrates deepening clinical efficacy and reinforces the company's best-in-class potential for treating Hidradenitis Suppurativa. The community is actively discussing the drug's regulatory pathway toward a BLA submission and the potential for a strategic buyout, while simultaneously debating market maker activity and recent analyst upgrades that have significantly raised price targets.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing significant volatility as investors weigh the company's shift toward high-performance AI data center infrastructure against macro-driven sell-offs and geopolitical instability in the Middle East. While community sentiment remains polarized, many participants are focused on the company's execution timeline for new site energization and the potential for major hyperscaler contract announcements to serve as a catalyst for recovery.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is facing significant volatility as shareholders navigate a mix of skepticism over project timelines and intense scrutiny regarding leadership, tenant acquisitions, and insider selling following the recent expiration of IPO lock-up agreements. While some traders are betting on a recovery driven by data center power demand and long-term infrastructure potential, others are concerned about cash burn, legal complaints, and the lack of definitive customer contracts.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is currently rallying as investors position the stock as a primary 'bring-your-own-power' solution for the surging AI data center buildout, further fueled by recent policy discussions surrounding energy infrastructure independence. The community is actively debating the stock's valuation and volatility, while tracking technical breakout levels and watching for institutional accumulation as the company solidifies its role in the critical power generation sector.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae ($FNMA) is seeing intense trading activity as investors react to ongoing speculation about an exit from conservatorship, with prominent figures like Bill Ackman and Michael Burry reportedly maintaining long positions. Community sentiment remains deeply divided, with bulls pointing to potential future catalysts and institutional buying, while bears emphasize the lack of concrete news and the stock's recent volatility.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing intense volatility as investors weigh the impact of rising geopolitical tensions and energy prices against the semiconductor sector's role in a potential market recovery. The community remains deeply divided, with some traders aggressively buying the dip on the belief that a quick diplomatic resolution will spark a rebound, while others warn of a structural bear flag and further downside as bearish momentum builds.

Pelican Acquisition Corporation is a special-purpose acquisition company that aims to merge with or acquire businesses, particularly in the global technology sector. The company's primary purpose of facilitate a merger, share exchange, asset acquisition, share purchase, reorganization, or any other form of business combination with one or more businesses.

Greenland Energy Co.

Greenland Energy is capturing significant market attention following its recent NASDAQ debut and business combination, as traders speculate on the potential for massive oil reserves in the Jameson Land Basin. The community is actively debating the company's long-term exploration goals versus short-term volatility, with many monitoring volume, potential squeezes, and the involvement of experienced industry leadership.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is facing intense downward pressure driven by a combination of geopolitical instability in the Middle East and market FUD surrounding Google's new memory-compression technology. While the community remains deeply divided between those viewing the current valuation as a generational buying opportunity and those fearing further technical breakdowns, investors are closely watching key support levels as they navigate the disconnect between the company's strong fundamentals and persistent institutional selling.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is generating significant market interest following a series of operational and financial milestones, including strong cash margins and the securing of long-term offtake agreements. Investors are actively debating the company's growth thesis and debt reduction progress, while recent momentum has been bolstered by increased lithium demand visibility and broader sector excitement regarding energy storage and electrification.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Nebulized Tyvaso improved absolute forced vital capacity (FVC) by 130.1 mL over placebo.</li><li>Consistent benefits were observed across patient subgroups regardless of background therapy, smoking status, or supplemental oxygen use.</li><li>Integrated analyses combining TETON-1 and TETON-2 reinforced Tyvaso’s effectiveness, showing a 111.8 mL FVC improvement.</li></ul>United Therapeutics Corp. (UTHR) announced on Monday that its TETON-1 trial of nebulized Tyvaso in the treatment of idiopathic pulmonary fibrosis (IPF) achieved its primary goal.The treatment not only met its main efficacy endpoint but also reduced the risk of clinical worsening.<h2 class="st-heading-2">Nebulized Tyvaso Shows Broad Efficacy</h2>The therapy demonstrated improvement in absolute forced vital capacity (FVC), outperforming placebo by 130.1 mL from baseline to week 52, giving new hope for patients with the debilitating lung disease.Benefits were consistent across subgroups, regardless of background therapy, smoking status, or supplemental oxygen use, while safety profiles aligned with previous Tyvaso studies, with no new adverse signals observed.<blockquote>“The unprecedented results of TETON-1, which surpassed even the overwhelmingly positive results of TETON-2, represent a profound step forward for people living with IPF, a devastating disease with few treatment options.”-Martine Rothblatt, Chairperson and CEO, United Therapeutics</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/UTHR">United Therapeutics’ stock</a> traded over 19% higher in Monday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Integrated Analyses Strengthen Findings</h2>Combining data from TETON-1 and TETON-2 reinforced the therapy’s effectiveness, showing an improvement of 111.8 mL in FVC and consistent positive effects across most secondary endpoints.&nbsp;Overall survival trends favored Tyvaso. Following these results, United Therapeutics intends to submit a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) by the end of summer 2026, seeking priority review to expand nebulized Tyvaso’s labeled indication to include IPF.UTHR stock has gained over 7% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-says-us-is-in-talks-with-new-iran-leadership-warns-complete-obliteration-of-energy-infrastructure-if-hormuz-remains-shut/cZERnXgRIZy">Trump Says US Is In Talks With ‘New’ Iran Leadership, Warns ‘Complete’ Obliteration Of Energy Infrastructure If Hormuz Remains Shut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the United Therapeutics Corporation logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did UTHR Stock Surge Over 19% Pre-Market Today? 

The company reported that its TETON-1 study to treat lung disease met its primary endpoint.

Equity

The company reported that its TETON-1 study to treat lung disease met its primary endpoint.


United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-1 study evaluating the use of nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint, demonstrating superiority over placebo for the...

Pallas Capital Advisors LLC Boosts Stake in United Therapeutics Corporation $UTHR

Pallas Capital Advisors LLC raised its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 147.6% during the fourth quarter, according to the company in its most recent 13F...

United Therapeutics Corporation $UTHR Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 88.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,960 shares of the biotechnology co...

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $535.81, for a total transaction of $5,090,195.00. Following the...

Wedge Capital Management L L P NC Has $29.57 Million Holdings in United Therapeutics Corporation $UTHR

Wedge Capital Management L L P NC lessened its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 8.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,6...

United Therapeutics Corporation $UTHR Shares Acquired by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 123.7% during the fourth quarter, according to its most recent 13F filing...

United Therapeutics (NASDAQ:UTHR) CFO Sells $5,359,000.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $535.90, for a total transaction of $5,359,000.00. Following the transaction, the...

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $535.81, for a total transaction of $5,090,195.00. Following the sale, the...

Assenagon Asset Management S.A. Buys 3,824 Shares of United Therapeutics Corporation $UTHR

Assenagon Asset Management S.A. boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 18.4% in the fourth quarter, according to its most recent disclosure with the...

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

Fred Wilson - Union Square Ventures

Abigail Johnson - Fidelity

Jim Cramer - Media Personality

Josh Brown - Ritholtz Wealth Management

A lifetime achievement for industry titans. This honor is reserved for an individual whose groundbreaking contributions have shaped the investing landscape and how we engage with the markets.

Stocktwits

Stocktwits Polls

Positive trial results for the TETON-1 study show Tyvaso met primary endpoints for treating pulmonary fibrosis.

UTHR
United Therapeutics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest UTHR News

UTHRUnited Therapeutics Corp